Tier 2 — strong

Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial

McDermott MM, Martens CR, Domanchuk KJ, Zhang D, Peek CB, Criqui MH, Ferrucci L, Greenland P, Guralnik JM, Ho KJ, Kibbe MR, Kosmac K, Lloyd-Jones D, Peterson CA, Sufit R, Tian L, Wohlgemuth S, Zhao L, Zhu P, Leeuwenburgh C
Nature communications 2024 15; 1; 5046

Bibliography

PubMed
PMID 38871717
PubMed Central
PMC11176364
DOI
10.1038/s41467-024-49092-5
Funding
American Heart Association support; ChromaDex supplied NR and ReserveAge supplied resveratrol.
Competing interests
The lead investigator reported research or other support from Helixmith, ArtAssist and Mars; other authors reported no competing interests.

Study snapshot

DesignRandomized placebo-controlled human trial
ModelHuman participants
Sample90 adults with lower-extremity peripheral artery disease
InterventionNR 1000 mg/day, with or without resveratrol 125 mg/day, versus placebo
Duration6 months
EndpointsSix-minute walking distance; adherence

What the study showed, in plain terms

NR improved six-minute walking distance relative to placebo in the NICE trial. Resveratrol did not add a clear benefit.

Key findings

The NR-versus-placebo difference at six months was 17.6 metres.

What this study can and cannot tell us

Pilot trial using a one-sided 90% confidence interval; larger confirmatory trials are needed. The published correction should be read with the report.

Related papers in the corpus

Tier 4
Publisher Correction: Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
McDermott MM et al. · Nature communications · 2024
Tier 4
Effects of NAD+ supplementation with oral nicotinamide riboside on vascular health and cognitive function in older adults with peripheral artery disease: Results from a pilot 4-week open-label clinical trial
Szarvas Z et al. · The Journal of pharmacology and experimental therapeutics · 2025
Tier 2
Nicotinamide riboside combined with exercise to treat hypertension in middle-aged and older adults: a pilot randomized clinical trial
Lin Y et al. · GeroScience · 2025
Tier 2
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD + in healthy middle-aged and older adults
Martens CR et al. · Nature communications · 2018

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology